You have 9 free searches left this month | for more free features.

Immunoconjugates

Showing 1 - 25 of 113

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Cancer Trial (Antibody-Drug Conjugate)

Not yet recruiting
  • Cancer
  • Antibody-Drug Conjugate
  • (no location specified)
Aug 23, 2023

Acute Lymphoblastic Leukemia Treated With Anti-CD22

Recruiting
  • Acute Lymphoblastic Leukemia
  • Anti-CD22 Immunotoxin
  • Meldola (FC), FC, Italy
  • +4 more
Feb 25, 2021

Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8 Trial in Seattle

Recruiting
  • Muscle Invasive Bladder Carcinoma
  • +2 more
  • Lymphadenectomy
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 9, 2023

Renal Pelvis and Ureter Urothelial Carcinoma Trial in Los Angeles (procedure, drug, biological)

Not yet recruiting
  • Renal Pelvis and Ureter Urothelial Carcinoma
  • Biopsy
  • +5 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Mar 15, 2023

Metastatic Penile Squamous Cell Carcinoma, Stage III Penile Cancer AJCC v8, Stage IV Penile Cancer AJCC v8 Trial in Phoenix,

Not yet recruiting
  • Metastatic Penile Squamous Cell Carcinoma
  • +3 more
  • Enfortumab Vedotin
  • Phoenix, Arizona
  • +2 more
Oct 23, 2023

Advanced Solid Tumor Trial in New York (STI-6129)

Not yet recruiting
  • Advanced Solid Tumor
  • STI-6129
  • New York, New York
    Columbia University Medical Center
Jan 26, 2023

Relapsed Solid Tumor, Refractory Cancer, Solid Tumor, Adult Trial (STI-3258)

Withdrawn
  • Relapsed Solid Neoplasm
  • +2 more
  • STI-3258
  • (no location specified)
Jan 24, 2023

Light Chain (AL) Amyloidosis Trial (STI-6129)

Not yet recruiting
  • Light Chain (AL) Amyloidosis
  • STI-6129
  • (no location specified)
Jan 11, 2023

Advanced and Metastatic Solid Tumor Trial in Shanghai (FZ-AD004)

Not yet recruiting
  • Advanced and Metastatic Solid Tumor
  • Shanghai, China
    Shanghai Chest Hospital
Jun 13, 2023

Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Seattle (drug, other,

Recruiting
  • Recurrent Hodgkin Lymphoma
  • +3 more
  • Brentuximab Vedotin
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 4, 2022

Advanced Solid Tumors Trial (FDA022 Monoclonal antibody-drug conjugate for injection)

Not yet recruiting
  • Advanced Solid Tumors
  • FDA022 Monoclonal antibody-drug conjugate for injection
  • (no location specified)
Sep 29, 2022

Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate

Recruiting
  • Aggressive Non-Hodgkin Lymphoma
  • +8 more
  • Polatuzumab Vedotin
  • +6 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 26, 2023

Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma, Malignant Renal Pelvis Tumor Trial in Atlanta (procedure,

Not yet recruiting
  • Bladder Squamous Cell Carcinoma
  • +10 more
  • Biospecimen Collection
  • +5 more
  • Atlanta, Georgia
  • +3 more
Feb 20, 2023

Light Chain (AL) Amyloidosis Trial in New York (STI-6129)

Recruiting
  • Light Chain (AL) Amyloidosis
  • STI-6129
  • Duarte, California
  • +3 more
Jan 12, 2023

Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Tumor in the Brain Trial in Duarte

Recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +2 more
  • Copper Cu 64-DOTA-Trastuzumab
  • +4 more
  • Duarte, California
    City of Hope Medical Center
Nov 22, 2022

Acute Myeloid Leukemia, Myeloid Tumor Trial in Seattle (Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Myeloid Neoplasm
  • Biospecimen Collection
  • +9 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Sep 5, 2023

DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to DLBCL Trial

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • +2 more
  • Biospecimen Collection
  • +5 more
  • (no location specified)
Sep 5, 2023

Reporting of Antibody-Drug Conjugate Associated Sepsis-related

Completed
  • Sepsis (SMQ)
  • +2 more
  • Antibody-Drug Conjugate
  • Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate
  • Changsha, Hunan, China
    Central South University
Jun 19, 2022

Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer Trial in United States (IMMU-130)

Withdrawn
  • Metastatic Colorectal Cancer
  • +2 more
  • Santa Monica, California
  • +6 more
Aug 12, 2021

Osteosarcoma, Recurrent Osteosarcoma Trial in United States (Trastuzumab Deruxtecan)

Suspended
  • Osteosarcoma
  • Recurrent Osteosarcoma
  • Trastuzumab Deruxtecan
  • Birmingham, Alabama
  • +27 more
Oct 21, 2022

HER2-Positive Breast Carcinoma, Metastatic Malignant Solid Tumor, Refractory Malignant Solid Tumor Trial in United States

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +4 more
  • Biopsy
  • +3 more
  • Bethesda, Maryland
  • +4 more
Jan 21, 2023

Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular T-Cell

Recruiting
  • Recurrent Angioimmunoblastic T-Cell Lymphoma
  • +13 more
  • Brentuximab Vedotin
  • Pembrolizumab
  • Chicago, Illinois
    Northwestern University
Jun 15, 2022

Breast Tumors Trial in Shenyang (Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting

Recruiting
  • Breast Neoplasms
  • Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788)
  • Shenyang, Liaoning, China
    Shengjing Hospital affiliated to China Medical University
Jul 30, 2022

HER2 Positive Metastatic Breast Cancer Trial in Worldwide (ARX788)

Active, not recruiting
  • HER2 Positive Metastatic Breast Cancer
  • Glendale, California
  • +52 more
Oct 25, 2022

Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Locally Advanced Urothelial Carcinoma, Metastatic

Recruiting
  • Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation
  • +3 more
  • Cabozantinib S-malate
  • +3 more
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Aug 8, 2022